Published in Science on April 05, 2001
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Extending healthy life span--from yeast to humans. Science (2010) 12.12
Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev (2006) 6.62
mTOR is a key modulator of ageing and age-related disease. Nature (2013) 5.40
A dynamic transcriptional network communicates growth potential to ribosome synthesis and critical cell size. Genes Dev (2004) 5.08
Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00
Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression. Cell Metab (2007) 4.59
"Sleeping beauty": quiescence in Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2004) 4.23
With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab (2010) 4.11
Sugar sensing and signaling in plants. Plant Cell (2002) 4.05
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med (2011) 3.84
Yeast life span extension by depletion of 60s ribosomal subunits is mediated by Gcn4. Cell (2008) 3.58
SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab (2008) 3.35
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A (2008) 3.30
Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics (2011) 3.28
MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. PLoS Biol (2007) 3.19
Glucose signaling in Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2006) 3.16
Regulation of yeast chronological life span by TORC1 via adaptive mitochondrial ROS signaling. Cell Metab (2011) 3.13
A molecular mechanism of chronological aging in yeast. Cell Cycle (2009) 3.12
Multiple regulators of Ty1 transposition in Saccharomyces cerevisiae have conserved roles in genome maintenance. Genetics (2001) 3.10
Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet (2007) 3.07
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
Superoxide is a mediator of an altruistic aging program in Saccharomyces cerevisiae. J Cell Biol (2004) 2.88
The TOR pathway comes of age. Biochim Biophys Acta (2009) 2.83
Lessons on longevity from budding yeast. Nature (2010) 2.81
SOD2 functions downstream of Sch9 to extend longevity in yeast. Genetics (2003) 2.81
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med (2012) 2.58
Replicative and chronological aging in Saccharomyces cerevisiae. Cell Metab (2012) 2.56
Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J (2004) 2.50
Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab (2014) 2.48
Genome-wide coexpression dynamics: theory and application. Proc Natl Acad Sci U S A (2002) 2.46
Protein kinase A and Sch9 cooperatively regulate induction of autophagy in Saccharomyces cerevisiae. Mol Biol Cell (2007) 2.45
Sch9 partially mediates TORC1 signaling to control ribosomal RNA synthesis. Cell Cycle (2009) 2.42
Mitochondrial fission proteins regulate programmed cell death in yeast. Genes Dev (2004) 2.30
Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell (2014) 2.24
Tor1/Sch9-regulated carbon source substitution is as effective as calorie restriction in life span extension. PLoS Genet (2009) 2.18
Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest (2013) 2.14
Recent developments in yeast aging. PLoS Genet (2007) 2.13
A stress-responsive system for mitochondrial protein degradation. Mol Cell (2010) 2.05
Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet (2008) 2.05
Initiation of the TORC1-regulated G0 program requires Igo1/2, which license specific mRNAs to evade degradation via the 5'-3' mRNA decay pathway. Mol Cell (2010) 2.01
Extension of chronological life span by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density. Aging (Albany NY) (2009) 1.82
Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci (2010) 1.82
DNA replication stress, genome instability and aging. Nucleic Acids Res (2007) 1.80
Longevity regulation in Saccharomyces cerevisiae: linking metabolism, genome stability, and heterochromatin. Microbiol Mol Biol Rev (2003) 1.78
Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) (2011) 1.74
The Ras-Erk-ETS-Signaling Pathway Is a Drug Target for Longevity. Cell (2015) 1.71
Influence of genotype and nutrition on survival and metabolism of starving yeast. Proc Natl Acad Sci U S A (2008) 1.69
Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid. BMC Biotechnol (2008) 1.68
The Arabidopsis NAC transcription factor VNI2 integrates abscisic acid signals into leaf senescence via the COR/RD genes. Plant Cell (2011) 1.63
SIRT6 in DNA repair, metabolism and ageing. J Intern Med (2008) 1.61
Genome-wide screen in Saccharomyces cerevisiae identifies vacuolar protein sorting, autophagy, biosynthetic, and tRNA methylation genes involved in life span regulation. PLoS Genet (2010) 1.59
Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol (2013) 1.57
Role of mitochondria in the pheromone- and amiodarone-induced programmed death of yeast. J Cell Biol (2005) 1.57
A microarray-based genetic screen for yeast chronological aging factors. PLoS Genet (2010) 1.53
Multiple-stress analysis for isolation of Drosophila longevity genes. Proc Natl Acad Sci U S A (2004) 1.52
Why is aging conserved and what can we do about it? PLoS Biol (2015) 1.50
Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiol Rev (2013) 1.50
A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab (2015) 1.48
Amino acid sensing in dietary-restriction-mediated longevity: roles of signal-transducing kinases GCN2 and TOR. Biochem J (2013) 1.46
DNA replication stress is a determinant of chronological lifespan in budding yeast. PLoS One (2007) 1.46
Rim15 and the crossroads of nutrient signalling pathways in Saccharomyces cerevisiae. Cell Div (2006) 1.45
The sphingolipid long-chain base-Pkh1/2-Ypk1/2 signaling pathway regulates eisosome assembly and turnover. J Biol Chem (2008) 1.45
Increased levels of reduced cytochrome b and mitophagy components are required to trigger nonspecific autophagy following induced mitochondrial dysfunction. J Cell Sci (2012) 1.45
Calorie restriction and the exercise of chromatin. Genes Dev (2009) 1.44
The malate-aspartate NADH shuttle components are novel metabolic longevity regulators required for calorie restriction-mediated life span extension in yeast. Genes Dev (2008) 1.43
Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal (2009) 1.43
Inhibition of telomere recombination by inactivation of KEOPS subunit Cgi121 promotes cell longevity. PLoS Genet (2015) 1.41
Why yeast cells can undergo apoptosis: death in times of peace, love, and war. J Cell Biol (2006) 1.38
Transcriptional regulation in yeast during diauxic shift and stationary phase. OMICS (2010) 1.38
Positive selection of Caenorhabditis elegans mutants with increased stress resistance and longevity. Genetics (2003) 1.37
Growth signaling promotes chronological aging in budding yeast by inducing superoxide anions that inhibit quiescence. Aging (Albany NY) (2010) 1.33
Defects arising from whole-genome duplications in Saccharomyces cerevisiae. Genetics (2004) 1.32
A simple model system for age-dependent DNA damage and cancer. Mech Ageing Dev (2006) 1.29
A human protein interaction network shows conservation of aging processes between human and invertebrate species. PLoS Genet (2009) 1.29
Short-term calorie restriction in male mice feminizes gene expression and alters key regulators of conserved aging regulatory pathways. PLoS One (2009) 1.28
Lifespan extension by calorie restriction relies on the Sty1 MAP kinase stress pathway. EMBO J (2010) 1.27
Longevity mutation in SCH9 prevents recombination errors and premature genomic instability in a Werner/Bloom model system. J Cell Biol (2008) 1.26
TOR and ageing: a complex pathway for a complex process. Philos Trans R Soc Lond B Biol Sci (2011) 1.25
Hot topics in aging research: protein translation, 2009. Aging Cell (2009) 1.24
Yeast AMID homologue Ndi1p displays respiration-restricted apoptotic activity and is involved in chronological aging. Mol Biol Cell (2006) 1.24
Oncogene homologue Sch9 promotes age-dependent mutations by a superoxide and Rev1/Polzeta-dependent mechanism. J Cell Biol (2009) 1.23
Increased respiration in the sch9Delta mutant is required for increasing chronological life span but not replicative life span. Eukaryot Cell (2008) 1.23
Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J (2007) 1.23
A genomic analysis of chronological longevity factors in budding yeast. Cell Cycle (2011) 1.22
Hot topics in aging research: protein translation and TOR signaling, 2010. Aging Cell (2011) 1.22
pH neutralization protects against reduction in replicative lifespan following chronological aging in yeast. Cell Cycle (2012) 1.21
Down-regulating sphingolipid synthesis increases yeast lifespan. PLoS Genet (2012) 1.20
Coordinate regulation of multiple and distinct biosynthetic pathways by TOR and PKA kinases in S. cerevisiae. Curr Genet (2006) 1.19
Gadd45 proteins: relevance to aging, longevity and age-related pathologies. Ageing Res Rev (2011) 1.19
Pro-aging effects of glucose signaling through a G protein-coupled glucose receptor in fission yeast. PLoS Genet (2009) 1.19
The yeast VPS genes affect telomere length regulation. Curr Genet (2004) 1.18
Fasting and differential chemotherapy protection in patients. Cell Cycle (2010) 1.18
System-level analysis of genes and functions affecting survival during nutrient starvation in Saccharomyces cerevisiae. Genetics (2010) 1.16
Composition and acidification of the culture medium influences chronological aging similarly in vineyard and laboratory yeast. PLoS One (2011) 1.16
Target of rapamycin signaling regulates metabolism, growth, and life span in Arabidopsis. Plant Cell (2012) 1.16
The molecular chaperone Sse1 and the growth control protein kinase Sch9 collaborate to regulate protein kinase A activity in Saccharomyces cerevisiae. Genetics (2005) 1.15
A cytoprotective perspective on longevity regulation. Trends Cell Biol (2013) 1.15
Candida glabrata environmental stress response involves Saccharomyces cerevisiae Msn2/4 orthologous transcription factors. Mol Microbiol (2008) 1.13
The use of global transcriptional analysis to reveal the biological and cellular events involved in distinct development phases of Trichophyton rubrum conidial germination. BMC Genomics (2007) 1.11
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Biodemographic trajectories of longevity. Science (1998) 7.78
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol (1994) 3.48
Chronological aging-independent replicative life span regulation by Msn2/Msn4 and Sod2 in Saccharomyces cerevisiae. FEBS Lett (2004) 1.81
Linear accelerator radiosurgery of cerebral arteriovenous malformations: an update. Neurosurgery (1994) 1.78
Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene (2011) 1.65
Statistical models for estimating the genetic basis of repeated measures and other function-valued traits. Genetics (2000) 1.45
Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer (1993) 1.44
Dosimetric considerations on multiple arc stereotaxic radiotherapy. Radiother Oncol (1988) 1.39
Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst (1993) 1.37
A simple model system for age-dependent DNA damage and cancer. Mech Ageing Dev (2006) 1.29
Genetic variation and aging. Annu Rev Genet (1995) 1.25
Heat-induced longevity extension in Drosophila. I. Heat treatment, mortality, and thermotolerance. J Gerontol A Biol Sci Med Sci (1997) 1.23
The fractionation experiment: reducing heterogeneity to investigate age-specific mortality in Drosophila. Mech Ageing Dev (1998) 1.17
Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol (1992) 1.14
External stereotactic irradiation by linear accelerator. Neurosurgery (1985) 1.10
New technique for three-dimensional linear accelerator radiosurgery. Acta Neurochir Suppl (Wien) (1987) 1.03
c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study. Eur J Cancer (1994) 1.01
Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer (1992) 0.92
Effect of ligand conformation on melanoma cell alpha3beta1 integrin-mediated signal transduction events: implications for a collagen structural modulation mechanism of tumor cell invasion. Biochemistry (1998) 0.90
Linear accelerator radiosurgery of cerebral arteriovenous malformations. Neurosurgery (1989) 0.87
Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol (1991) 0.86
Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res (1992) 0.86
Stereotactic radiosurgery utilizing a linear accelerator. Appl Neurophysiol (1985) 0.85
Combined radiosurgery and external radiotherapy of intracranial germinomas. Surg Neurol (1990) 0.84
PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma. Growth Regul (1992) 0.84
Phenotypic characterization of epiphycan-deficient and epiphycan/biglycan double-deficient mice. Osteoarthritis Cartilage (2009) 0.82
Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck. Oncology (1991) 0.82
A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat (1994) 0.82
The propensity for consuming ethanol in Drosophila requires rutabaga adenylyl cyclase expression within mushroom body neurons. Genes Brain Behav (2012) 0.82
Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat (1989) 0.81
Experience of vaccination against invasive bacterial diseases in Veneto region (north east Italy). J Prev Med Hyg (2012) 0.81
Conservative surgery and irradiation (QUART) in the treatment of 243 stage I-II breast cancer patients. Anticancer Res (1992) 0.80
A selective genetic analysis of the Syracuse high- and low-avoidance (SHA/Bru and SLA/Bru) strains of rats (Rattus norvegicus). Behav Brain Res (1999) 0.79
Linear accelerator radiosurgery of three-dimensional irregular targets. Stereotact Funct Neurosurg (1990) 0.79
Linear accelerator radiosurgery of arteriovenous malformations. Appl Neurophysiol (1987) 0.78
Selection for increased longevity in Drosophila melanogaster: a response to Baret and Lints. Gerontology (1995) 0.77
Osteogenic osteosarcoma of the calvaria following radiotherapy for cerebellar astrocytoma: report of a case in childhood. Tumori (1985) 0.77
Radiosurgery using a 4MV linear accelerator. Technique and radiobiologic implications. Acta Radiol Suppl (1986) 0.77
Relationship of the epidermal growth factor-receptor to the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas. Anticancer Res (1992) 0.77
[Use of saline reinforcement screens in cesiography]. Quad Radiol (1968) 0.75
[Evaluation of late lesions following therapy with fast electrons]. Strahlentherapie (1968) 0.75
[Characteristics of P 32 "Bremsstrahlung" in material of uniform density: experimental dosimetry]. Acta Isot (Padova) (1967) 0.75
Radiotherapeutic treatment for breast cancer choroidal metastases. Tumori (1990) 0.75
Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer. J Cancer Res Clin Oncol (1992) 0.75
[High energy radiography (4 MV). Practical results]. J Radiol Electrol Med Nucl (1975) 0.75
[Small size breast cancer conservative surgical therapy and subsequent radiotherapy]. Chir Ital (1988) 0.75
Linear accelerator radiosurgery of cerebral arteriovenous malformations: current status. Acta Neurochir Suppl (1994) 0.75
[Renography in the evaluation of high energy radiotherapy with wedge filters in cancer of the bladder]. Acta Isot (Padova) (1966) 0.75
[Methodologic proposals on the subject of pancreatic scintigraphy]. Quad Radiol (1969) 0.75
[Stereotaxic radiosurgery using photon beam radiation from a linear accelerator]. Med Radiol (Mosk) (1989) 0.75
[Biopsy and stereotaxic radiotherapy of cerebral gliomas]. Minerva Med (1984) 0.75
From radiotherapy to stereotactic radiosurgery: physical and dosimetrical considerations. Radiother Oncol (1993) 0.75
[Influence of Fleming's lysozyme on leukopenia due to radiotherapy. Case contribution]. Quad Radiol (1966) 0.75
Analysis of dosimetric measurements in linac radiosurgery calibration. Radiother Oncol (1993) 0.75
Treatment of early stage Hodgkin's disease with radiation therapy plus short-cycle (3 MOPP) adjuvant chemotherapy. Tumori (1983) 0.75
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. Invest New Drugs (1991) 0.75
[Increasing childhood immunization coverage by establishing structured relationships with pediatricians and family practitioners]. Ann Ig (2012) 0.75
Osteosarcoma of the facial bones. Ann Oncol (1992) 0.75
Treatment of 49 unrandomized patients with advanced Hodgkin's disease. Tumori (1983) 0.75
Treatment of locally advanced squamous-cell carcinoma of the head and neck with concurrent radiochemotherapy - randomized comparison of Cisplatin versus Carboplatin. Int J Oncol (1993) 0.75
[Stereotaxic irradiation with a linear accelerator]. Radiol Med (1984) 0.75
[Medical thermography: a new contribution to the early diagnosis of breast cancer?]. Acta Chir Ital (1970) 0.75
Surgical and adjuvant radiation therapy of resectable retroperitoneal soft tissue sarcomas in adults. Tumori (1992) 0.75
[Advanced stages of rectosigmoid cancer. The role of postoperative radiotherapy]. Radiol Med (1989) 0.75
[Histochemical behavior of some enzymes of mucosa of the small intestine in irradiated animals]. Minerva Radiol (1966) 0.75
Locally advanced breast-carcinoma - results of a multimodal therapy including alternating neoadjuvant chemotherapy, surgery and radiotherapy. Int J Oncol (1992) 0.75
[Our experience with radiotherapy of alopecia. Case report]. Minerva Dermatol (1966) 0.75
Development of a second generation stereotactic apparatus for linear accelerator radiosurgery. Acta Neurochir Suppl (Wien) (1991) 0.75
Pathobiological characteristics of the 1st primary and risk of metachronous contralateral invasive breast-carcinoma - clinical implications. Int J Oncol (1993) 0.75
A retrospective analysis concerning physical aspects and clinical dosimetry in radiosurgery. J Neurosurg Sci (1989) 0.75
[Duplication and "pseudo-duplication" of the gallbladder]. Quad Radiol (1968) 0.75
[Radiocinematography in the study of venous dynamics in the lower limb]. Med Audio Vis (1967) 0.75
Synchronous radiotherapy and chemotherapy with cisplatin in the management of locally advanced or recurrent head and neck cancer. Am J Clin Oncol (1992) 0.75
Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer. Breast Cancer Res Treat (1992) 0.75
Multivariate-analysis of prognostic factors in 232 patients with clinical stage-I endometrial adenocarcinoma using the new figo surgical staging system. Int J Oncol (1992) 0.75
Stereotactic radiosurgery of intracranial tumors in childhood. J Neurosurg Sci (1986) 0.75
Dosimetry in interstitial curietherapy: comments on the Manchester and Paris systems as an introduction to a new system of dosimetry. Rays (1987) 0.75